Assessment of Abuse Potential of Rapastinel in Humans

Study Identifier
RAP-PK-12
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Other
  • Study Drug
  • Rapastinel
  • Ketamine
  • Placebo
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 55 Years

    Protocol Summary

    Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.

    Study Locations

    Location
    Status
    Location
    Vince and Associates Clinical Research Inc
    Overland Park, Kansas, United States, 66212
    Status
    Not applicable